AKT1 and pancreatic neoplasm: Our results showing ritonavir-mediated inhibition of AKT activity and decreased cell proliferation have relevance in light of earlier observations correlating gemcitabine-induced drug resistance with activation of the AKT pathway in pancreatic cancer cells [9].